Equity Profile

BBIO

BridgeBio Pharma, Inc.

Health CareBiotechnology$15.9B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to revenue.

$-0.57

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$220M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers. With a market cap of $16 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, BridgeBio reported an EPS of $-0.84, missing estimates by a significant margin. The stock reacted negatively, declining by nearly 1% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to cost management and operational efficiency.
Plans to enhance partnerships for drug development.

Expectations

Wall Street Expectations

Analysts expect BridgeBio to report a loss of $-0.57 per share on revenues of $220 million for Q2-2026. The market is closely watching for signs of improved performance after recent misses.

Bull Case

If BridgeBio can exceed revenue expectations and show progress in its clinical trials, it could signal a turnaround and boost investor confidence.

Bear Case

Continued losses and missed revenue targets could raise concerns about the company's long-term viability and lead to further stock declines.

Key Metrics to Watch

EPS

$-0.57

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to revenue.

Revenue

$220M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BridgeBio's revenue meet or exceed the consensus estimate of $220 million?

Revenue performance is critical for assessing the company's market traction and growth potential, especially after previous misses.

What updates will management provide on the progress of key clinical trials?

Investors are keen to understand the status of drug development, as successful trials could significantly impact future revenue and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BridgeBio to turn around its revenue trajectory given its focus on innovative therapies.

Supporting Evidence

The company's recent advancements in clinical trials could lead to faster product approvals.

Insider buying activity suggests confidence in the company's future prospects despite recent performance.

Options pricing indicates lower volatility expectations, which may not reflect the potential for significant positive news.

Key Risk

If revenue comes in above $220 million, it could challenge the current bearish sentiment and shift investor perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is crucial for determining the company's trajectory, especially given its recent performance and market expectations.

Bull Confirmed If

Exceeding revenue expectations of $220 million and demonstrating progress in clinical trials would confirm the bull case.

Bear Confirmed If

Falling short of revenue expectations and providing no positive updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move, suggesting that investors are uncertain about the upcoming earnings results.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could rise by around 1.48%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the market.

Miss

If the company misses expectations again, history suggests a potential decline of about 1.48%, raising concerns about its growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the status of key clinical trials and expected timelines.
2Any updates on partnerships or collaborations that could enhance revenue.
3Management's commentary on cost management strategies.
4Insights into market demand for their therapies.
5Future guidance on revenue expectations beyond Q2-2026.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to revenue.

$-0.57

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$220M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, BridgeBio reported an EPS of $-0.84, missing estimates by a significant margin. The stock reacted negatively, declining by nearly 1% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to cost management and operational efficiency.
Plans to enhance partnerships for drug development.

Expectations

Wall Street Expectations

Analysts expect BridgeBio to report a loss of $-0.57 per share on revenues of $220 million for Q2-2026. The market is closely watching for signs of improved performance after recent misses.

Bull Case

If BridgeBio can exceed revenue expectations and show progress in its clinical trials, it could signal a turnaround and boost investor confidence.

Bear Case

Continued losses and missed revenue targets could raise concerns about the company's long-term viability and lead to further stock declines.

Key Metrics to Watch

EPS

$-0.57

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to revenue.

Revenue

$220M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BridgeBio's revenue meet or exceed the consensus estimate of $220 million?

Revenue performance is critical for assessing the company's market traction and growth potential, especially after previous misses.

What updates will management provide on the progress of key clinical trials?

Investors are keen to understand the status of drug development, as successful trials could significantly impact future revenue and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BridgeBio to turn around its revenue trajectory given its focus on innovative therapies.

Supporting Evidence

The company's recent advancements in clinical trials could lead to faster product approvals.

Insider buying activity suggests confidence in the company's future prospects despite recent performance.

Options pricing indicates lower volatility expectations, which may not reflect the potential for significant positive news.

Key Risk

If revenue comes in above $220 million, it could challenge the current bearish sentiment and shift investor perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is crucial for determining the company's trajectory, especially given its recent performance and market expectations.

Bull Confirmed If

Exceeding revenue expectations of $220 million and demonstrating progress in clinical trials would confirm the bull case.

Bear Confirmed If

Falling short of revenue expectations and providing no positive updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move, suggesting that investors are uncertain about the upcoming earnings results.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could rise by around 1.48%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the market.

Miss

If the company misses expectations again, history suggests a potential decline of about 1.48%, raising concerns about its growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the status of key clinical trials and expected timelines.
2Any updates on partnerships or collaborations that could enhance revenue.
3Management's commentary on cost management strategies.
4Insights into market demand for their therapies.
5Future guidance on revenue expectations beyond Q2-2026.